OLMA Olema Pharmaceuticals Inc

Price (delayed)

$11.92

Market cap

$1.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.03

Enterprise value

$992.59M

?
Relative Growth: Rel. Growth: 4
Relative Strength: Rel. Strength: 67
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is ...

Highlights
Olema Pharmaceuticals's equity has increased by 25% YoY
The debt has declined by 6% since the previous quarter
OLMA's quick ratio is down by 29% year-on-year but it is up by 10% since the previous quarter
Olema Pharmaceuticals's net income has decreased by 44% YoY and by 14% from the previous quarter
OLMA's EPS is down by 9% QoQ and by 7% YoY

Key stats

What are the main financial stats of OLMA

OLMA stock price

How has the Olema Pharmaceuticals stock price performed over time
Intraday
-2.3%
1 week
13.2%
1 month
-9.63%
1 year
179.81%
YTD
-52.32%
QTD
-20.05%

Financial performance

How have Olema Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$201.81M
Net income
-$185.15M
Gross margin
N/A
Net margin
N/A
Olema Pharmaceuticals's net income has decreased by 44% YoY and by 14% from the previous quarter
The operating income has decreased by 41% YoY and by 13% QoQ

Price vs fundamentals

How does OLMA's price correlate with its fundamentals

Growth

What is Olema Pharmaceuticals's growth rate over time

Valuation

What is Olema Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OLMA's EPS is down by 9% QoQ and by 7% YoY
Olema Pharmaceuticals's equity has increased by 25% YoY
OLMA's price to book (P/B) is 16% more than its 5-year quarterly average of 1.9 but 3.9% less than its last 4 quarters average of 2.3

Efficiency

How efficient is Olema Pharmaceuticals business performance
Olema Pharmaceuticals's ROE has decreased by 9% YoY and by 7% from the previous quarter
The return on assets has declined by 8% year-on-year and by 6% since the previous quarter
The return on invested capital has declined by 6% since the previous quarter but it has grown by 2.7% year-on-year

Dividends

What is OLMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OLMA.

Financial health

How did Olema Pharmaceuticals financials performed over time
Olema Pharmaceuticals's total liabilities has soared by 92% YoY but it has decreased by 9% from the previous quarter
Olema Pharmaceuticals's total assets has increased by 30% YoY
The debt is 99% smaller than the equity
Olema Pharmaceuticals's equity has increased by 25% YoY
The debt has declined by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.